It's fun to work in a company where people truly BELIEVE in what they're doing!

We're committed to bringing passion and customer focus to the business.

The Vice President, Clinical Strategy & Product owns LucyRx's clinical and non-clinical product portfolio end to end — defining what gets built, why it wins in market, and how clinical evidence, formulary strategy, and client-facing clinical engagement come together in a sellable offering. Reporting to the SVP, Clinical Solutions & Client Experience, this leader oversees three functions: the product management team, the clinical account executive team, and formulary strategy. The role converts market and client insight into a prioritized roadmap, owns the investment case and pricing model for each program, and ensures clinical value is a decisive differentiator in the sales cycle.

Role and Responsibilities

Product & Clinical Strategy

Own the clinical and non-clinical product portfolio — prioritizing against market, client, and evidence inputs, and setting roadmap sequencing.
Define the clinical strategy across priority therapeutic categories (e.g., diabetes, women's health, cardiovascular, specialty) and translate it into differentiated, buildable product offerings.
Monitor clinical evidence, treatment trends, regulatory change, and competitive moves to inform product design and positioning.
Integrate formulary strategy with product strategy so clinical programs, benefit design, and net-cost performance reinforce one another.

Leadership

Lead a three-function organization — product management, clinical account management, and formulary strategy — against a single roadmap and one clinical point of view.
Set the bar for how work reaches market: discovery rigor, business case quality, launch readiness, and the evidence behind every claim the team makes, with formulary and benefit design decisions made alongside product decisions rather than after them.
Recruit, coach, and retain senior clinical and commercial talent, and build succession depth across all three functions.

Commercial & Financial Ownership

Own the investment case and pricing model for each clinical program; approve investments within the VP delegated authority threshold and pricing within the approved rate card, and recommend anything above to the SVP.
Partner with Sales, Underwriting, and Finance to ensure clinical products are priced, packaged, and positioned to win.
Establish KPIs and reporting on adoption, revenue, margin, and clinical outcomes across the portfolio.

Execution & Governance

Partner with Technology on build sequencing, scope trade-offs, and release planning.
Govern clinical evidence standards and outcomes measurement for launched programs, and recommend iterate, scale, or sunset.
Ensure products meet PBM regulatory, contractual, and clinical program standards in partnership with Compliance and Legal.

Qualifications and Education Requirements

10+ years of progressive experience in PBM, pharmacy product strategy, pharmacy services, or a related healthcare services environment, including at least 5 years in a leadership role.
Demonstrated experience owning or materially shaping product strategy, clinical program strategy, formulary strategy, pharmacy benefit solutions, or related healthcare offerings
Proven ability to lead multi-disciplinary teams across product, clinical, formulary, client-facing, finance, technology, and operational function.
Strong working knowledge of PBM operations, formulary management, utilization management, clinical programs, specialty pharmacy, pharmacy claims data, and the regulatory environment..
Proven track record developing business cases, pricing models, performance measures, and portfolio recommendations tied to revenue, margin, savings, adoption, and clinical outcome.
Demonstrated success supporting sales, retention, finalist meetings, or client strategy as a senior clinical or product subject matter expert.
Exceptional executive communication, stakeholder management, decision-making, and presentation skills.
Bachelor of Pharmacy or PharmD required.

Preferences

PharmD, active or prior pharmacist licensure, or comparable clinical pharmacy leadership experience.
Direct experience in PBM product strategy, formulary strategy, specialty pharmacy, clinical program design, or P&T governance.
Experience developing or scaling programs in high-cost or high-growth categories such as GLP-1s, diabetes, women’s health, biosimilars, or specialty drugs.
Experience using pharmacy claims, clinical outcomes, market data, and financial modeling to guide product strategy, pricing, and client-facing value stories.

Physical Requirements

The physical demands described here are representative of those that must be met by an employee to successfully perform the essential functions of this job. This is a largely sedentary role; however, some standing, walking, bending, and reaching may be required. Regularly operates in an office setting which involves utilizing a computer, mouse, keyboard, and occasionally operates other standard office equipment such as a printer, copier, and phone. Minimal travel may be required.

What We Do

LucyRx is an independent, next-generation pharmacy benefits manager (PBM) transforming how healthcare works. We’re fixing what’s broken in the PBM industry by putting people first and challenging outdated norms. For too long, traditional PBMs have prioritized profit over patients, and we believe that’s just plain wrong. LucyRx offers bold, innovative solutions powered by LucyIQ, our proprietary AI platform, to deliver actionable insights that lower costs, improve care, and simplify prescription management. While we’re new to the PBM space, LucyRx is built on decades of leadership experience and a commitment to meaningful change. We’re a nimble, remote-first team with a bold mission to redefine pharmacy benefits—and we’re just getting started.

What It’s Like to Work at LucyRx

At LucyRx, we’re a fast-moving team dedicated to making healthcare simpler, fairer, and more effective. Joining us means being part of a dynamic, mission-driven group that works collaboratively to challenge outdated industry practices and redefine what’s possible in pharmacy benefits. We value accountability, innovation, and a relentless focus on making an impact. Here, you’ll find a supportive culture that encourages you to bring your whole self to work, share bold ideas, and grow alongside smart, driven colleagues who are passionate about fixing the PBM industry. If you’re ready to roll up your sleeves and make a real difference, we’d love to have you on our team.

Salary $233,603.00 - $292,004.00

About the company

LucyRx is a pharmacy benefit manager that helps self-insured employers and health plans manage prescription benefits with transparent pricing. Its LucyIQ platform uses AI to provide real-time data and insights to optimize formulary design, identify cost-saving opportunities, and manage high-cost specialty drugs. It differs from traditional PBMs by eliminating hidden fees, aligning its financial interests with clients and members, and pursuing growth through acquisitions like CerpassRx and Citizens Rx. Its goal is to simplify prescription benefits, reduce drug costs, and improve patient outcomes through data-driven decisions and seamless access to medications via an integrated specialty network and next-day home delivery.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Maryland

Founded

2023

Get referred to LucyRx

See people who can refer or advise you

Simplify's Take

What believers are saying

LucyRx secured more than $500 million from LRVHealth for acquisitions and growth.
The company added Christin Bassett in January 2026 to strengthen regulatory defense and dealmaking.
LucyRx won Personify Health, employers, and consultants around GLP-1 management and cost containment.

What critics are saying

The Abarca merger closes only after regulatory approval, creating execution and integration risk through Q3 2026.
PBM transparency claims face FTC scrutiny and state investigations that can compress margins quickly.
CVS Caremark, Express Scripts, and OptumRx can outspend LucyRx, limiting scale; failure means irrelevance.

What makes LucyRx unique

LucyRx and Abarca are merging into Healthcare Revolution Partners, targeting nine million members.
David Blair's Catalyst Health Solutions exit proves he can build and sell PBMs.
LucyIQ and the Outcomes Accord emphasize auditable pricing, clinical outcomes, and member experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options
Training Programs
Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

15%

1 year growth

15%

2 year growth

28%

PR Newswire

Jun 17th, 2026

Abarca Health and LucyRx Announce Strategic Combination to Create the Only Modern PBM Built for Commercial and Government Scale

/PRNewswire/ -- Abarca Health and LucyRx today announced a strategic combination to create the only modern, independent pharmacy benefit manager with the...

Forbes

Jun 17th, 2026

Abarca Health and LucyRx to merge into alternative to big three PBMs.

Abarca Health and LucyRx to merge into alternative to big three PBMs. ByBruce Japsen, Senior Contributor. Bruce Japsen writes about healthcare business and policy. Jun 17, 2026, 02:00pm EDT Jun 17, 2026, 02:14pm EDT Summary. Independent pharmacy benefit managers Abarca Health and LucyRx are merging to form Healthcare Revolution Partners, creating a new entity serving over 9 million customers across the U.S. The deal, expected to close in the third quarter, aims to establish a modern, independent PBM with significant scale and technology. This strategic move comes amidst intense regulatory scrutiny of the PBM industry and growing demands for greater transparency and affordability in prescription drug pricing. The combined company seeks to offer a competitive alternative to the dominant, vertically integrated PBMs, emphasizing flexibility, accountability, and sustainable drug pricing. Both Abarca and LucyRx will retain their brands and leadership, aiming to accelerate a "healthcare revolution" by providing a trusted operating foundation and tailored customer experiences. Abarca Health and LucyRx - two privately held independent pharmacy benefit management companies - have agreed to merge as an alternative to the nation's largest PBMs and as the public seeks better prescription drug prices. The combination of Abarca and LucyRx will create a pharmacy benefit management business that will serve more than 9 million plan members across the U.S. in a deal designed to "create the only modern, independent pharmacy benefit manager with the scale, technology, and track record to credibly serve commercial and government clients of any size," the companies announced Wednesday. The Abarca-LucyRx deal will put the combined company in the top 10 PBMs when it comes to number of prescriptions managed but still far smaller than the three largest PBMs that control 80% of the U.S. market. Those three are: CVS Health's Caremark; Express Scripts, which is owned by Cigna; and OptumRx, which is owned by UnitedHealth Group. "The market today doesn't have a lot of choice," LucyRx chief executive officer David Blair said. "Now, we're providing the market a clear alternative to the traditional PBM model." Abarca and LucyRx executives say they will be a stronger combined business "for commercial and government scale" while also bringing more competition to the market by operating in a more transparent way given they aren't part of larger companies that also own health insurers, pharmacies or other providers of medical care. "They are vertically integrated and have many conflicts of interest," Abarca chief executive officer Jason Borschow said of the three largest PBMs. Pharmacy benefit managers work as middlemen of sorts between insurers, pharmacies, and drug manufacturers to negotiate drug prices and manage prescription benefits. MORE FOR YOU Lately, however, they have been under unprecedented scrutiny with practically every state in the country, along with the U.S. government, looking at PBM business practices while transforming regulations and pushing for greater transparency. The big three PBMS, in particular, have been subject of a Federal Federal Trade Commission inquiry into anticompetitive behavior that government attorneys say resulted in inflated drug prices. The companies have denied the allegations. The Prompt: Get the week's biggest AI news on the buzziest companies and boldest breakthroughs, in your inbox. "The timing is intentional," Abarca and LucyRx said in a joint statement. "The PBM market is at a breaking point shaped by a new regulatory paradigm, sustained pressure from high-cost specialty drugs and GLP-1s, and clients demanding a different kind of PBM relationship - one that delivers more flexibility, true accountability, and sustainable affordability. Employers, consumers, and healthcare providers deserve a better experience." The Abarca-LucyRx combination will put the companies in all 50 states once it closes with complimentary businesses that currently have "zero overlap," the companies said. LucyRx, which has about 1.6 million members, manages pharmacy benefits for more than 4,000 clients across the country including mid-sized employers and unions with about 400 to 500 workers while Abarca's client base consists of about 7.5 million members via health plans and government health programs. Both Abarca, which is based in San Juan, Puerto Rico, and LucyRx, which is based in Bethesda, Maryland, will retain their brands and operate as wholly owned subsidiaries of a company called Healthcare Revolution Partners once the deal closes in the third quarter of this year, pending regulatory approvals. Financial terms of the transaction weren't disclosed. "Leveraging our combined scale, technology, and track record, we will accelerate the healthcare revolution Abarca started more than 20 years ago," Blair said. "Together, we will deliver a trusted operating foundation, tailored customer experiences powered by best-in-class technology, and total-cost-of-care savings anchored in putting patients first." Blair and Borschow will continue to serve as CEOs of their respective companies and become co-chairs of Healthcare Revolution Partners once the deal closes. "LucyRx shares our vision of making healthcare more seamless and personalized for everyone," Borschow said. "We look forward to leveraging LucyRx's clinical capabilities, Connected Specialty Care Network, and expertise serving employers and labor groups nationwide to deepen our service offerings and accelerate our entry into new market segments." Abarca grabbed headlines two years ago when it was named as a participating partner in the launch of Blue Shield of California's drug benefit venture with Amazon Pharmacy. In what Blue Shield has called its "Pharmacy Care Reimagined Initiative," the venture officially began business last year. When the venture was first announced in August of 2024, it sent the stocks of the owners of the nation's largest managers of pharmacy benefits plummeting when Blue Shield confirmed it was dropping CVS Health's Caremark and going its own way. Other stocks also took a tumble that day, including the share price of Cigna and the stock of UnitedHealth Group. Read our community guidelines. FORBES' VIDEO WILL PLAY AFTER THIS AD FORBES' FEATURED Video Less than $2/week.

PR Newswire

Mar 24th, 2026

LucyRx named to Fast Company's annual list of the World's Most Innovative Companies for 2026.

LucyRx named to Fast Company's annual list of the World's Most Innovative Companies for 2026. Mar 24, 2026, 08:30 ET Recognition highlights LucyRx's work to improve prescription care through clear, straightforward pricing, flexible benefit design, and integrated clinical support. BETHESDA, Md., March 24, 2026 /PRNewswire/ - LucyRx, an independent pharmacy benefit manager (PBM) focused on transforming how prescription care is delivered and paid for, has been named to Fast Company's annual list of the World's Most Innovative Companies for 2026. The company was recognized among a select group of health care organizations redefining how pharmacy benefits are designed, managed, and experienced. LucyRx earned the distinction for advancing pharmacy benefit design through clear pricing, flexible formularies, and real-time analytics that help employers better understand and manage prescription drug spending. Fast Company's annual list recognizes companies across industries and regions shaping how business and innovation evolve. The recognition comes as LucyRx continues to scale its model nationally, supporting more than 1.65 million members and helping over 4,000 employers bring greater visibility and control to their pharmacy benefit design. LucyRx has also earned a Net Promoter Score of 65, reflecting strong client satisfaction in a category historically defined by opacity and misaligned incentives. "LucyRx was built on the belief that prescription care should be simpler, more accessible, and designed around the people who depend on it," said David Blair, Chief Executive Officer of LucyRx. "This recognition reflects the work our team is doing to bring real accountability, clinical insight, and modern infrastructure to pharmacy benefits so employers and patients can finally see and manage the real cost of care." Through its platform, LucyRx combines choice in formulary design, real-time analytics through its LucyIQ(TM) technology, and integrated clinical support to help plan sponsors manage costs while improving outcomes for members. Its Connected Specialty Care Network now includes over 130 specialty pharmacies nationwide, helping patients access complex therapies more quickly and consistently. Dedicated LucyRx Care Guides provide personalized support to patients navigating treatment and help reduce delays. "What makes LucyRx different is that we started from the patient and built outward. Employers get real-cost pricing, genuine choice in formulary design, and clinical support that actually follows the member through the process," said Susan Thomas, Chief Commercial Officer of LucyRx. "The result is a benefit that works the way it was always supposed to." About LucyRx LucyRx is a fast-scaling, independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its Connected Specialty Care Network, Formulary Marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ(TM), the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based certified pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves over 4,000 clients nationwide. This is prescription care, brilliantly reimagined. SOURCE LucyRx

One News Page

Jan 8th, 2026

LucyRx Appoints Christin Bassett as Chief Legal Officer

LucyRx appoints Christin Bassett as Chief Legal Officer. Bassett brings deep PBM regulatory and compliance expertise to support rapid growth BETHESDA, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) - LucyRx, an independent pharmacy benefit manager (PBM) known for simplifying access to prescription care, announced the addition of Christin Bassett as Chief Legal Officer. In her role, she will oversee all legal operations at LucyRx while working closely with senior leadership to support continued growth across mergers and acquisitions, government programs and new product development. Christin brings more than 25 years of experience advising boards and executive teams in highly regulated healthcare and pharmacy organizations. Her background spans legal and regulatory risk for both public and private companies, government affairs, sales and financing and pharmaceutical matters. Prior to joining LucyRx, she held senior legal and leadership roles at Rite Aid Corporation, Otsuka America Pharmaceutical, Inc. and Aetna Inc., and began her career in private practice at national law firms. "Christin brings deep legal and regulatory expertise to our team," said David Blair, chief executive officer of LucyRx. "Her experience will be instrumental as we continue scaling the company with the accountability, compliance and patient-first focus that defines LucyRx." Christin earned her Juris Doctor with high honors from The George Washington University Law School and holds a Bachelor of Arts in Political Science and English from Duke University. *About LucyRx* LucyRx is a fast-scaling, independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its Connected Specialty Care Network, Formulary Marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ(TM), the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based certified pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves more than 3,000 clients nationwide. This is prescription care, brilliantly reimagined. Learn more at LucyRx.com *Media Contact: * Tricia Bancroft 516-241-6157 [email protected]

Yahoo Finance

Oct 15th, 2025

LucyRx Launches an Outcomes Accord, Uniting Consultants, Brokers and Employers to Raise PBM Accountability

LucyRx launches an Outcomes Accord, uniting consultants, brokers and employers to raise PBM accountability. BETHESDA, Md., October 15, 2025-(BUSINESS WIRE)-LucyRx, a next-generation pharmacy benefit manager (PBM) known for simplifying and improving access to prescription care, announced an Outcomes Accord to unite plan sponsors, consultants, brokers and LucyRx to a shared standard for PBM accountability. Unveiled at LucyRx's 2025 Partner Summit, the Outcomes Accord defines how performance is measured and verified across plans and populations and moves beyond rebate math and claim discounts. The founding cohort includes dozens of employers spanning manufacturing, technology, insurance, health care delivery and transportation, leading pharmacy consultants and brokerage firms. Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, was the keynote speaker at LucyRx's Summit and challenged the participants with the question, "How do we bring more transparency into the process, and what are the things that might move the needle for the American people to begin to trust the system again?" "The Outcomes Accord confronts that reality with results," said David Blair, CEO of LucyRx. "The clients and consultants who've joined as Founders are not just early adopters. They are architects of a model where outcomes are proven, not just promised." * PMPM cost and yearly trend: The actual, checked total pharmacy cost per member each month, net of discounts and rebates. * Medication adherence: How well members stick to their medicine routines for important health conditions. * Avoided care costs: Money saved by preventing unnecessary emergency room visits, hospital stays or health problems. * Clinical savings: The direct health benefits and cost reductions from pharmacy actions. * Member experience: How satisfied members are with their access to medicine and the support they receive. * Biosimilar adoption: Safely switching to lower-cost, similar medicines to improve affordability and value. The Outcomes Accord sets a new fiduciary standard by tying success directly to clinical outcomes, cost containment and member experience - shifting the focus from how savings are promised to how results are delivered. It is governed by three principles: * Clarity, where every outcome is measurable, auditable and client verified. * Commitment, where PBMs and plan sponsors align to shared metrics rather than marketing claims. * Courage, where participants invite independent scrutiny and publish results on a regular cadence.

LucyRx

Vice President - Clinical Strategy, Product

About the job